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The primary goal of this study was to characterize dysphagia onset and progression in the low copy number
SOD1-G93A (LCN-SOD1) mouse model of ALS. A secondary goal was to determine the effect of serial
radiation exposure throughout the lifespan on dysphagia severity. To accomplish this goal, we used our
lab’s established Videofluoroscopic Swallow Study (VFSS) assay to objectively assess swallow function in
54 mice, divided into serial versus single radiation exposure groups. The serial X-ray exposure group
(n=24; 13 LCN-SOD1, 11 control) underwent VFSS testing once a month, starting at 2 months of age until
disease end-stage. The single X-ray exposure group (n=30; 15 LCN-SOD1, 15 control) underwent VFSS
testing only once at disease end-stage. VFSS videos from both groups were analyzed to quantify 8 swallow
metrics. Results showed that all swallow metrics were similar within and between genotypes from 2 to 6
months of age, which coincided with the pre-clinical disease stage in LCN-SOD1 mice. At disease end-
stage, LCN-SOD1 mice had significantly altered swallow function for 5 of the 8 VFSS metrics under
investigation, compared to age-matched controls. Between disease onset and end-stage, LCN-SOD1 mice
demonstrated highly variable disease phenotypes and survival durations, which rendered it impossible to
characterize the onset and rate of dysphagia progression with the small sample size. However, two main
findings emerged from this study. First, dysphagia onset in LCN-SOD1 mice did not occur until after 6
months of age. This finding suggests that treatments for dysphagia in this mouse model of ALS should
begin after 6 months of age (i.e., after clinical disease onset) for optimal translational potential to humans
with ALS. Our second novel finding was that dysphagia severity at disease end-stage was similar for single
versus serial radiation exposure in LCN-SOD1 mice, which provides evidence that our lab can continue to
perform longitudinal VFSS studies in this small animal without confounding outcomes relative to dysphagia.
However, the majority of mice developed evidence of surface-level radiation toxicity (fur depigmentation
and dry eyes) as the number of x-ray exposures increased, even though it did not affect swallow function.
Therefore, we are taking proactive measures to reduce radiation exposure during VFSS and thereby
prevent skin and eye morbidities for future longitudinal dysphagia investigations.
